Skip to main content

Advertisement

SpringerLink
Log in

Completely reversible agranulocytosis in a multiple myeloma patient treated with thalidomide–dexamethasone

  • CE - Letter to the Editor
  • Published:
Internal and Emergency Medicine Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Olson KB, Hall TC, Horton J, Khung CL, Hosley HF (1965) Thalidomide (N-phthaloylglutamimide) in the treatment of advance cancer. Clin Pharmacol Ther 40:292–297

    Google Scholar 

  2. Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Munshi N, Anaissie E, Wilson C, Dhodapkar M, Zeddis J, Barlogie B (1999) Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 341:1565–1571

    Article  PubMed  CAS  Google Scholar 

  3. Weber D, Rankin K, Gavino M, Delasalle K, Alexianan R (2003) Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 21:16–19

    Article  PubMed  CAS  Google Scholar 

  4. Cavo M, Zamagni E, Tosi P, Cellini C, Cangini D, Tacchetti P, testoni N, Tonelli M, Vivo A, Palareti G, Tura S, Baccarani M (2004) First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma. Haematologica 89:826–831

    PubMed  CAS  Google Scholar 

  5. Kumar S, Rajkumar SV (2005) Thalidomide and dexamethasone: therapy for multiple myeloma. Expert Rev Anticancer Ther 5:759–66

    Article  PubMed  CAS  Google Scholar 

  6. Cavo M, Zamagni E, Tosi P, Tacchetti P, Cellini C, Cangini D, Vivo A, Testoni N, Nicci C, Terragna C, Grafone T, Perrone G, Ceccolini M, Tura S, Baccarani M (2005) Superiority of thalidomide and dexametasone over vincristina–doxorubicin–dexamethasone (VAD) as primary therapy for autologous transplantation for multiple myeloma. Blood 106:35–39

    Article  PubMed  CAS  Google Scholar 

  7. Dimopoulos MA, Eleutherakis-Papaiakovou V (2004) Adverse effects of thalidomide administration in patients with neoplastic diseases. Am J Med 117:508–515

    Article  PubMed  CAS  Google Scholar 

  8. Mazzotta S, Gozzetti A, Pirrotta MT, Bocchia M, Samassimo S, Bucalossi A, Lauria F (2005) Low-dose thalidomide induced agranulocytosis in a multiple myeloma patient treated at diagnosis. Leuk Lymphoma 46:1837–1838

    Article  PubMed  CAS  Google Scholar 

  9. Hattori Y, Kakimoto T, Okamoto S, Sato N, Ikeda Y (2004) Thalidomide-induced severe neutropenia during treatment of multiple myeloma. Int J Hematol 79:283–288

    Article  PubMed  Google Scholar 

  10. Richardson PG, Schlossman RL, Weller E, Hideshima T, Mitsiades C, Davies F, LeBlanc R, Catley LP, Doss D, Kelly K, McKenney M, Mechlowicz J, Freeman A, Deocampo R, Rich R, Ryoo JJ, Chauhan D, Balinski K, Zeldis J, Anderson KC (2002) Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 100:3062–3067

    Google Scholar 

  11. McCarthy DA et al (2006) The neutropenia induced by thalidomide analogue CC-4047 in patients with multiple myeloma is associated with an increased percentage of neutrophils bearing CD64. Int Immunopharmacol 6:1194–1203

    Article  PubMed  CAS  Google Scholar 

  12. Rajkumar SV, Blood E, Vesole D, Fonseca R, Greipp PR (2006) Phase III clinical trial of Thalidomide plus dexamethasone compared with desamethasone alone in newly diagnosed multiple Myeloma: a clinical trial coordinate by the eastern cooperative oncology group. J Clin Oncol 24:431–436

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Ospedale Maggiore di Parma, Via Gramsci 14, 43100, Parma, Italy

    Francesca Magalini

  2. Department of Internal Medicine, University of Parma, Parma, Italy

    Adriano Stella & Paolo Sansoni

Authors
  1. Francesca Magalini
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Adriano Stella
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Paolo Sansoni
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Francesca Magalini.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Magalini, F., Stella, A. & Sansoni, P. Completely reversible agranulocytosis in a multiple myeloma patient treated with thalidomide–dexamethasone. Intern Emerg Med 3, 383–385 (2008). https://doi.org/10.1007/s11739-008-0136-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11739-008-0136-0

Keywords

Search

Navigation